{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:48:10Z","timestamp":1762231690784,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022RC302","2023RC312","2022RC303"],"award-info":[{"award-number":["2022RC302","2023RC312","2022RC303"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dmd.2025.100094","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T02:26:56Z","timestamp":1746844016000},"page":"100094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of antihypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo"],"prefix":"10.1016","volume":"53","author":[{"given":"Dafa","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiazong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zebei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengfei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuyun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Al Mamun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0057-267X","authenticated-orcid":false,"given":"Shuanghu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100094_bib1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dmd.2025.100094_bib2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: Management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.dmd.2025.100094_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.dmd.2025.100094_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.dmd.2025.100094_bib5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dmd.2025.100094_bib6","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1124\/dmd.124.001841","article-title":"Metabolism and excretion of [(14)C]mobocertinib, a selective covalent inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion mutations, in healthy male subjects","volume":"52","author":"Chen","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100094_bib7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/aps.2016.10","article-title":"An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s","volume":"37","author":"Chen","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.dmd.2025.100094_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jch.12638","article-title":"Diabetes and hypertension: a comparative review of current guidelines","volume":"18","author":"Cryer","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.dmd.2025.100094_bib9","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.dmd.2025.100094_bib10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3390\/pharmaceutics14071474","article-title":"A physiologically based pharmacokinetic and pharmacodynamic model of the CYP3A4 substrate felodipine for drug-drug interaction modeling","volume":"14","author":"Fuhr","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmd.2025.100094_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0091-7435(87)90087-9","article-title":"Incidence and precursors of hypertension in young adults: the Framingham Offspring Study","volume":"16","author":"Garrison","year":"1987","journal-title":"Prev Med"},{"key":"10.1016\/j.dmd.2025.100094_bib12","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.dmd.2025.100094_bib13","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.dmd.2025.100094_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.dmd.2025.100094_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.dmd.2025.100094_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jpba.2018.12.030","article-title":"Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?","volume":"165","author":"Kaza","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2025.100094_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.dmd.2025.100094_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/dmd.114.063016","article-title":"Simultaneous screening of activities of five cytochrome P450 and four uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry","volume":"43","author":"Lee","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100094_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-019-0783-9","article-title":"Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.dmd.2025.100094_bib20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cllc.2016.12.014","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non-small-cell lung cancer","volume":"18","author":"Lin","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.dmd.2025.100094_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/chromsci\/bmu047","article-title":"Identification of multiple constituents in Chinese medicinal prescription Shensong Yangxin capsule by ultra-fast liquid chromatography combined with quadrupole time-of-flight mass spectrometry","volume":"53","author":"Liu","year":"2015","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.dmd.2025.100094_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpba.2015.03.032","article-title":"Validated UPLC-MS\/MS method for determination of hordenine in rat plasma and its application to pharmacokinetic study","volume":"111","author":"Ma","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2025.100094_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/00003088-200140080-00004","article-title":"Drug interactions with irbesartan","volume":"40","author":"Marino","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100094_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpba.2014.02.020","article-title":"In vitro metabolism of the alkaloid piplartine by rat liver microsomes","volume":"95","author":"Marques","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2025.100094_bib25","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.dmd.2025.100094_bib26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1248\/bpb.28.882","article-title":"Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes","volume":"28","author":"Nakamura","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dmd.2025.100094_bib27","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2025.100094_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.dmd.2025.100094_bib29","first-page":"690","article-title":"Role of kaempferol to increase bioavailability and pharmacokinetics of nifedipine in rats","volume":"17","author":"Park","year":"2019","journal-title":"Chin J Nat Med"},{"key":"10.1016\/j.dmd.2025.100094_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bcpt.13244","article-title":"Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings","volume":"125","author":"Park","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.dmd.2025.100094_bib31","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.dmd.2025.100094_bib32","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dmd.2025.100094_bib33","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I\/II trial","volume":"11","author":"Riely","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.dmd.2025.100094_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.dmd.2025.100094_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.dmd.2025.100094_bib36","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","article-title":"Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites","volume":"102","author":"Sungaila","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dmd.2025.100094_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002280050731","article-title":"In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists","volume":"56","author":"Taavitsainen","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100094_bib38","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dmd.2025.100094_bib39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/psp4.12563","article-title":"Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype-derived activity scores","volume":"9","author":"Thomas","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100094_bib40","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2174\/1389200216666150223152627","article-title":"CYP3A4-mediated pharmacokinetic interactions in cancer therapy","volume":"15","author":"Tian","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmd.2025.100094_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bph.14884","article-title":"Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: effects on activity and drug responses","volume":"177","author":"Tolledo","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dmd.2025.100094_bib42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.clpt.2003.08.001","article-title":"Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91\/3 genotype","volume":"74","author":"Uchida","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100094_bib43","doi-asserted-by":"crossref","first-page":"8c","DOI":"10.1016\/0002-9149(92)90276-5","article-title":"Comparative pharmacokinetics of captopril, enalapril, and quinapril","volume":"69","author":"Vertes","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dmd.2025.100094_bib44","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00432-021-03752-x","article-title":"The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer","volume":"148","author":"Wang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.dmd.2025.100094_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jchromb.2015.03.025","article-title":"Determination of N-methylcytisine in rat plasma by UPLC-MS\/MS and its application to pharmacokinetic study","volume":"990","author":"Wang","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.dmd.2025.100094_bib46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jchromb.2015.01.020","article-title":"Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS\/MS","volume":"983-984","author":"Wang","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.dmd.2025.100094_bib47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14737140.2023.2157815","article-title":"Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer","volume":"23","author":"Yang","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.dmd.2025.100094_bib48","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.clinthera.2022.09.009","article-title":"Strong pharmacokinetic drug-drug interactions with drugs approved by the US Food and Drug Administration in 2021: mechanisms and clinical implications","volume":"44","author":"Yu","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmd.2025.100094_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpba.2014.03.030","article-title":"Study of in vitro metabolism of m-nisoldipine in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography-mass spectrometry","volume":"97","author":"Yuan","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2025.100094_bib50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jchromb.2014.09.026","article-title":"Simultaneous determination of scutellarin and tetrahydropalmatine of Deng-yan granule in rat plasma by UFLC-MS\/MS and its application to a pharmacokinetic study","volume":"971","author":"Zhang","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:43:57Z","timestamp":1762231437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0090955625091032"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100094","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of antihypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100094"}}